Iovance Biotherapeutics Inc (IOVA) Stock Analysis
Verdict: WATCH (do not buy)
Amtagvi commercial expansion drives Q2 revenue to $99.3M, but 12-month cash runway and 19.6x P/S cap short-term upside after +72% 30d rally.
Investment score: 54/100
Analysis as of
Is Iovance Biotherapeutics Inc stock worth reviewing? AI model thesis
The AI model views Iovance Biotherapeutics as a WATCH. While commercialization of Amtagvi is scaling rapidly ($99.3M Q2 2026 revenue), valuation multiples (19.6x P/S TTM) and a 12-month cash runway constrain risk-adjusted expected returns over a 90-day horizon following a 72.4% 30-day price run-up.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 80/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Iovance Biotherapeutics Inc opportunities and risks
What speaks for IOVA
- Amtagvi commercial acceleration expanding solid tumor market access
What speaks against IOVA
- Impending cash runway wall and equity dilution risk within 12 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IOVA | n/a | 19.6x | n/a | 48.4% | -89.1% | -4.7% |
| SYRE | n/a | 75.5x | n/a | 0.0% | -197.7% | -3.1% |
| IONS | n/a | 8.1x | n/a | 98.2% | -64.6% | -7.9% |
| PRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.6% |
| GRAL | n/a | 37.6x | n/a | -10.8% | -236.9% | -4.8% |
| RYTM | n/a | 24.9x | n/a | 89.0% | -85.6% | -2.5% |
| Peer median | n/a | 24.9x | n/a | 0.0% | -85.6% | -4.6% |
Frequently asked questions about Iovance Biotherapeutics Inc (IOVA)
Is IOVA stock a good investment?
The cached TradeMates AI model rates Iovance Biotherapeutics Inc as WATCH (do not buy) with an investment score of 54/100. The AI model views Iovance Biotherapeutics as a WATCH. While commercialization of Amtagvi is scaling rapidly ($99.3M Q2 2026 revenue), valuation multiples (19.6x P/S TTM) and a 12-month cash runway constrain risk-adjusted expected returns over a 90-day horizon following a 72.4% 30-day price run-up. This is algorithmic model output, not personal investment advice.
Is IOVA stock a buy?
The TradeMates model verdict for IOVA is WATCH (do not buy) with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.